|
|
|
1. PRESTIGE STUDY : An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks with ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women with Oestrogen Receptor Positive Advanced Breast Cancer.
2. SERENITY STUDY : Study No. - P1446A: An open lable, Multicentre Phase II study of Selective Cyclin Dependent Kinase Inhibitor. In subjects with Advanced Refractory Malignancies.
3. Study No. - BIBF-1193.13 : A multicentre, randomized, double blind, Phase 3 Trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in patients with stage IIIB/IV orrecurrent non small cell lung cancer after failure of first line chemotherapy.
4. Bafetinib-P2-HRPC-01-A Phase II Study of Bafetinib (INNO-406) as Treatment for Patient with Hormone- Refractory Prostate Cancer.
5. Fighting cervical cancer, FOGSI cervical cancer registry, a reaching the unreached FOGSI initiative 2010. . A pap smear & HIV DNA & colposcopy based study.
6. Docet Study : A multicenter, double blind, randomized, fully replicate, crossover, comparative pharmacokinetic and safety study in female patients to show essential similarity of a novel formulation of intravenous Actavis Docetaxel (Docetaxel 20 mg/ml ) concentrate for solution for infusion to provide 100mg/m˛ Docetaxel and commercially available TaxotereŽ (Docetaxel 40 mg/mL), concentrate for solution for infusion to provide 100 mg/m˛ Docetaxel.
7. A phase II study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer patient receiving Treatment with Gemcitabine.
8. Safety and Efficacy of Recombinant Human Granulocyte-colony Stimulating Factor-rhGCSF (ReliGrastTM or NeupogenŽ) in Patients with Chemotherapy Induced Neutropenia (Protocol No : GMX-GCSF-CT001)
9. Study No. - PT-101 : Phase 1 Study of Intravaginal Tamoxifen (PT-101): Randomized, double blind study of safety, pharmacokinetic (PK) and pharmacodynamics (PD) in menopausal patients with moderate to severe Vulvar and vaginal atrophy.
10. Study No. - DOCET_R_02271 : This is a multi-country, multi-centre, single arm non-interventional, prospective registry study.
Active implementation of Quality of Life (QOL) assessment in clinical practice for patients with advanced NSCLC and comparison of QOL and response endpoints.
11. VANILLA STUDY : A Multinational, Randomized, Double-Blind, Placebo-Controlled, Study Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer
|
|
|
|
